The Department of Health and Human Services today announced a $226 million contract to expand the nation’s capacity to quickly produce vaccine for a flu pandemic. HHS expects the six-year agreement with Sanofi Pasteur to increase the company’s capacity to use recombinant vaccine technology, which is faster than traditional egg-based technology, to produce a pandemic vaccine in the United States to nearly 100 million doses. Sanofi is the only company with a seasonal recombinant flu vaccine licensed in the U.S. “Keeping vaccine manufacturing in the United States is essential to protect Americans from pandemic influenza and to save lives,” said BARDA Director Rick Bright. “Better, faster vaccine technologies, produced in the U.S. will improve access, protect more people and, ultimately, strengthen our nation’s health security.” In September, President Trump created an interagency task force to develop and implement a five-year plan to improve flu vaccines and produce them faster.

 

Related News Articles

Headline
This season’s flu vaccines for the Southern Hemisphere have reduced the risk of being hospitalized for flu by 52%, based on mid-season data from five countries…
Headline
The Food and Drug Administration announced its approval of Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use…
Chairperson's File
It’s been about 65 years since an effective vaccine was first used worldwide against poliomyelitis, or polio. Until then, polio was responsible for about 500,…
Headline
Learn how Advocate Children's Hospital is managing the “immunity gap” created by social distancing to persevere through the triple threat of COVID-19, RSV and…
Headline
AHA’s United Against the Flu campaign today released a new social media toolkit to help hospitals and health systems encourage their communities to get…
Headline
The Food and Drug Administration Friday authorized for emergency use the first over-the-counter test to detect both flu and SARS-CoV-2, the virus that causes…